Why the oral Wegovy pill is 25mg, not 50mg: what OASIS 4 shows

• OASIS 4 (NEJM, doi:10.1056/NEJMoa2500969) found oral semaglutide 25mg led to a mean 13.6% body weight reduction compared to placebo in adults with overweight or obesity.
• The FDA approved an oral semaglutide tablet (Wegovy tablet) for weight management. The 25mg dose studied in OASIS 4 is the approved commercial dose.
• The 50mg dose in OASIS 1 relied on a different formulation with different administration requirements — it is not the same product as the approved 25mg tablet.
• Mean weight loss with oral semaglutide 25mg (~13.6%) is lower than published results for injectable Wegovy (~15–16% in STEP trials). That reflects differences in delivery route and formulation, not a straightforward better-vs.-worse comparison.
• Two oral GLP-1 options are now FDA-approved or recently approved — oral semaglutide (Wegovy tablet) and orforglipron (Foundayo) — with different mechanisms, administration requirements, and trial data.

OASIS 4 (ClinicalTrials.gov NCT05564117) was a phase 3, randomized, double-blind, placebo-controlled trial of once-daily oral semaglutide 25mg in adults with overweight or obesity.

The primary endpoint was change in body weight from baseline at 64 weeks. Like the injectable STEP trials, participants received lifestyle counseling — structured nutrition and physical activity guidance — alongside the drug.

At 64 weeks, participants on oral semaglutide 25mg achieved a mean body weight reduction of 13.6% compared to placebo.

That's substantially more than most patients achieve with lifestyle intervention alone. Gastrointestinal side effects — primarily nausea, vomiting, and diarrhea — were the most commonly reported adverse events, consistent with what's seen in injectable semaglutide trials. Physical function also improved in the active treatment group.

The American College of Cardiology's summary of OASIS 4 noted that results with oral semaglutide 25mg were "comparable with that seen with the 50mg oral dose" — a key finding that informed the approval decision.

The short answer is that the 25mg and 50mg oral semaglutide doses were studied on different formulations.

OASIS 1 tested a 50mg dose using an earlier version of the sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) absorption-enhancing system — the same delivery mechanism used in Rybelsus, the lower-dose oral semaglutide approved for type 2 diabetes. That formulation requires fasting before dosing, a specific small volume of water, and a waiting period before eating.

The 25mg tablet approved for weight management uses a specific formulation optimized for the weight-management indication. Because OASIS 4 showed comparable weight loss to OASIS 1's 50mg dose, and because formulation and manufacturing considerations also factor into approval decisions, the 25mg dose became the approved commercial dose.

This is not a case of a manufacturer choosing a less effective dose. The data showed the lower dose, on its formulation, produced comparable results.

This is the question most patients ask. The honest answer: the injectable shows higher average weight loss in published trials.

Injectable semaglutide (Wegovy 2.4mg weekly) produced a mean ~15–16% weight loss in the STEP 1 pivotal trial. Oral semaglutide 25mg produced 13.6% in OASIS 4.

That gap is real and reflects the fundamental pharmacology of oral vs. injectable delivery. Oral semaglutide has lower and more variable bioavailability than the subcutaneous injection — you absorb less of the drug, which translates to somewhat lower average efficacy at currently approved doses.

That doesn't make the pill inferior for every patient. Convenience, needle aversion, and adherence are real factors. For patients who would not use or continue an injectable, an oral option that produces ~13–14% average weight loss is clinically meaningful.

What to avoid assuming: that the pill and injection are equivalent, or that you can simply swap between them without a clinical conversation.

• Long-term weight maintenance on oral semaglutide beyond the 64-week trial window
• How individual response compares between oral and injectable in real-world practice — trial averages don't tell individual stories
• Insurance coverage parity between oral and injectable formulations (varies by plan)
• How oral semaglutide compares head-to-head with orforglipron (Foundayo) — no direct comparison trial has been published

• Based on OASIS 4, what realistic weight-loss range should I expect with the oral tablet?
• Do my specific health conditions make the injectable or oral option a better fit?
• How does my plan cover the oral formulation compared to the injection?
• Is there a clinical reason to try oral before or after injectable therapy?

• Body weight at monthly intervals during dose escalation
• Gastrointestinal symptoms — more common early in treatment, typically improve over time
• Appetite and food noise changes, which often precede measurable weight changes

OASIS 4 is one piece of an increasingly complex picture for patients weighing oral vs. injectable GLP-1 options. Two oral options are now FDA-approved — the Wegovy tablet and Foundayo (orforglipron). They have different mechanisms, different administration requirements, and different trial datasets.

The right choice, if an oral option is appropriate, is a clinician conversation that accounts for your specific situation — not a comparison of trial averages alone.

Sources

• Ryan DH, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 2025. doi:10.1056/NEJMoa2500969. nejm.org
• ClinicalTrials.gov NCT05564117. clinicaltrials.gov
• ACC Journal Scan. OASIS 4: Significant Weight Loss With Oral Semaglutide. acc.org